FDA Grants Approval For New Treatment For Metastatic HER-2 Breast Cancer

FDA Grants Approval For New Treatment For Metastatic HER-2 Breast Cancer

Drug Regulatory Authority in the US has approved a new treatment called Enhertu for patients who are living with unresectable HER2 positive breast cancer. The treatment can be given to those patients who have taken at least two or more anti-HER2 based regimens. Unresectable or metastatic HER2 positive breast cancer cannot be removed through surgery. In this case, cancer cells spread to other body parts of the patient. Enhertu is a form of human epidermal growth factor receptor 2 (HER2) antibodies that target changes in HER2 that accelerate cancer growth….

Read More